SG3 Management’s Pfizer PFE Stock Holding History

SG3 Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,085,515	Closed	-$37.8M	–	1174
2020 Q3	$37.8M	Buy	1,085,515 +1,033,447	+1,985%	+$36.2M	1.4%	7
2020 Q2	$1.61M	Buy	+52,068	New	+$1.77M	0.11%	220
2019 Q3	–	Sell	-12,332	Closed	-$507K	–	435
2019 Q2	$507K	Buy	+12,332	New	+$490K	0.06%	221
2019 Q1	–	Sell	-8,432	Closed	-$349K	–	373
2018 Q4	$349K	Buy	+8,432	New	+$350K	0.09%	129
2017 Q3	–	Sell	-31,620	Closed	-$1.01M	–	234
2017 Q2	$1.01M	Buy	+31,620	New	+$997K	0.25%	97
2017 Q1	–	Sell	-15,810	Closed	-$487K	–	293
2016 Q4	$487K	Buy	+15,810	New	+$483K	0.08%	139

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SG3 Management's PFE Position: Q1 2022 in Review

SG3 Management sold out of Pfizer (PFE) in Q1 2022, closing a stake of 135,000 shares — an estimated $7.97M sold.

SG3 Management first reported a position in PFE in Q2 2017 and held it in 3 quarters. The position peaked at $7.97M in Q4 2021. 3,196 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

SG3 Management reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 135,000 Pfizer shares in Q1 2022, an estimated $7.97M.
SG3 Management first reported a position in Pfizer in Q2 2017 and held it in 3 quarters.
SG3 Management's Pfizer position peaked at $7.97M in Q4 2021.
3,196 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.